ProKidney (MEX:PROK) Other Financing: MXN476.88 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PROK ProKidney Corp MEX:PROK
19 GF Score
Price MXN31.10
! 3 Warning Signs
View Full Analysis

What is ProKidney Other Financing?

ProKidney MEX:PROK 19 Other Financing is MXN476.88 Mil as of Jun. 2026. GuruFocus rates MEX:PROK with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

ProKidney's Other Financing for the three months ended in Jun. 2026 was MXN9.53 Mil.

ProKidney's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was MXN476.88 Mil.

ProKidney Other Financing Historical Data

* Premium members only.

The historical data trend for ProKidney's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProKidney Other Financing Chart

ProKidney Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 1,466.75 10,694.59 0.00 2.92 24.27

ProKidney Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 145.95 317.60 3.81 9.53
MEX:PROK
19GF Score
ProKidney Corp MEX:PROK
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProKidney Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN476.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of MXN476.88 Mil mean?
ProKidney (MEX:PROK) has a Other Financing of MXN476.88 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for ProKidney and its competitors.
Is ProKidney's Other Financing too high?
ProKidney's current Other Financing is MXN476.88 Mil. Overall, ProKidney has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does ProKidney's Other Financing compare to EYPT and ENTA?
ProKidney's Other Financing of MXN476.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for ProKidney and its competitors. ProKidney's current Other Financing is MXN476.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProKidney stock overvalued right now?
ProKidney (MEX:PROK) has a current Other Financing of MXN476.88 Mil. The current Other Financing is MXN476.88 Mil. ProKidney's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For ProKidney (MEX:PROK), the current Other Financing is MXN476.88 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProKidney Business Description

Other Exchanges PROK:USA
Address 2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
19GF Score

Get the complete analysis for MEX:PROK

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN31.10
Price